:This is a an open-label, single-arm study to evaluate the efficacy and safety of zanubrutinib and G-CHOP in untreated Intermediate-high risk Follicular Lymphoma patients.
Histologically confirmed CD20 positive (+) follicular lymphoma, grade 1, 2, or 3a
Have had no prior systemic treatment for lymphoma
Meeting Groupe d'Etude des Lymphomes Folliculaires (GELF) criteria for initiation of treatment
18-75 years old.
Known active central nervous system lymphoma or leptomeningeal disease
Evidence of diffuse large B-cell transformation
Grade 3b FL
Concurrent malignancy or malignancy within the last 3 years (except for ductal breast cancer in situ, non-melanoma skin cancer, prostate cancer not requiring treatment, and cervical carcinoma in situ) whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational regimen are not eligible for this trial